Seegene Inc
상단으로
Contact Us

Seegene participates in EUROGIN 2016

Jun 18, 2016

?
From June 15 to 18, Seegene participated in the EUROGIN 2016 (European Research Organization on Genital Infection and Neoplasia) expo in Salzburg, Austria.
?
EUROGIN is an international academic conference that features presentations on clinical research studies, epidemiological investigations, and the latest HPV screening techniques and cervical cancer screening/prevention efforts. To reduce the incidence and death rates of cervical cancer, EUROGIN strives to increase awareness of cervical cancer among governments and public institutions and conducts research that emphasizes the importance of cervical cancer prevention.
?
This year’s EUROGIN conference featured numerous presentations on studies by researchers in the Netherlands, Italy, Sweden, and China on the application?or pilot tests in preparation for the application?of HPV screening to national screening programs for cervical cancer. In particular, emphasis was placed on the need for regular HPV tests, regardless of whether an individual has received a cervical cancer vaccination. In addition, multi-national projects were introduced that aim to prevent cervical cancer through vaccinations and HPV testing.
?
The participants of EUROGIN are world-class authorities and experts on cervical cancer and HPV. As in previous years, Seegene was the only Korean company to participate, alongside multinational companies such as Roche, Qiagen, and Hologic.
?
At this year’s EUROGIN, Seegene introduced its Anyplex™ II HPV28 Detection product, which simultaneously tests for 28 types of HPV known to cause cervical cancer and genital warts, and Anyplex™ II HPV HR Detection, which quickly and accurately screen for 14 high-risk HPVs infection simultaneously.
?
Both products were the focus of significant attention from conference participants for their ability to simultaneously screen and conduct genotyping for multiple HPVs using real-time PCR.
?
In particular, the HPV HR Detection product was introduced by Dr. Marc Arbyn, a world-renowned Belgian authority on HPV testing and genotyping, in his seminar presentation. He highlighted the facts that the product meets international guidelines and is clinically proven to be highly effective. Based on the interest in this product, Seegene was invited to a seminar by the Institute of Oncology Ljubljana in Slovenia.